Everolimus, a pivotal mTOR inhibitor, integrates antitumor, osteoprotective, and immunomodulatory actions in osteosarcoma, targeting oncogenic signaling, metabolic reprogramming, angiogenesis, and the bone–immune interface. Here, MTOR is linked to osteosarcoma.